Details of the Drug

General Information of Drug (ID: DMIAOU6)

Drug Name

SLN124

Indication

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small interfering RNA

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TMPRSS6 messenger RNA (TMPRSS6 mRNA)	TTNIUKC	TMPS6_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04718844) A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
2	SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1. Hemasphere. 2019 Oct 1;3(6):e301.